Xeris Pharmaceuticals Inc (XERS) — Cash Flow-to-Debt Ratio
Xeris Pharmaceuticals Inc (XERS) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2026, meaning its operating cash flow of $8.26 Million could theoretically repay 0% of its total liabilities ($421.64 Million) in one year. See Xeris Pharmaceuticals Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Xeris Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Xeris Pharmaceuticals Inc across 10 annual periods. For the full cash flow conversion analysis, see XERS cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Xeris Pharmaceuticals Inc (2016–2025)
Year-by-year debt coverage analysis for Xeris Pharmaceuticals Inc. Check how high is Xeris Pharmaceuticals Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | $28.63 Million | $369.84 Million | ▲ +173.8% |
| 2024 | -0.10x | $-36.98 Million | $352.68 Million | ▲ +26.5% |
| 2023 | -0.14x | $-47.02 Million | $329.38 Million | ▲ +58.5% |
| 2022 | -0.34x | $-102.89 Million | $299.33 Million | ▲ +24.8% |
| 2021 | -0.46x | $-95.53 Million | $209.13 Million | ▲ +46.4% |
| 2020 | -0.85x | $-80.56 Million | $94.55 Million | ▲ +22.8% |
| 2019 | -1.10x | $-104.35 Million | $94.55 Million | ▲ +12.5% |
| 2018 | -1.26x | $-56.28 Million | $44.62 Million | ▼ -425.9% |
| 2017 | -0.24x | $-24.66 Million | $102.83 Million | ▲ +2.4% |
| 2016 | -0.25x | $-16.09 Million | $65.47 Million | — |